Posts tagged leukemia supplemental

Coriolus PSK / Leukemia Study

By on January 6, 2011
This entry is filed under Leukemia and tagged , , , .

Here’s a study showing increased survival rates using PSK in association with chemotherapy.

Chemoimmunotherapy with Krestin in acute leukemia. Tokai Journal of Experimental and Clinical Medicine 1981;6(2):141-6.

Purpose: Disease response and survival Type of Study: RCT Methods: (Leukemia) (n=28) Patients were placed at random in the chemotherapy and chemo-immunotherapy groups with 14 patients each. Remission had been induced by combination therapy (neocarzinostatin, cytosine arabinoside, prednisolone or vinicristine, daunorubicin, prednisolone). After complete remission, two to three courses of consolidation therapy consisting of mercaptopurine chemotherapy with or without Krestin (PSK) daily until relapse. Results: The median duration for complete remission and survival were longer in the chemoimmunotherapy (PSK) than the chemotherapy group. The complete remission rate was higher in the chemoimmunotherapy group (36 weeks; range 17 – 128) than the chemotherapy group (25 weeks; range 9 to 66+). The average survival time of the PSK group was 21 months (range 8 to 37+) while that of the control group was 12 months (range four to 26). The cell-mediated immunity was somewhat enhanced in the chemoimmunotherapy group, while it was not enhanced in the chemotherapy group. No subjective or objective side effects due to PSK were observed for over one year.

PSP Coriolus Extract – How It Works (Mechanism Of Action) – MD Anderson, Texas

By on July 26, 2010
This entry is filed under Gastric Cancer, Leukemia, Lung Cancer, Medical Studies, PSP, Types Of Extract and tagged , , , , , , , , .

The multiple and complex mechanisms of action of Coriolus Versicolor PSP have been demonstrated through in vitro and animal studies. Coriolus PSP has suppressed the growth of human cancer cell lines in mice (sarcoma 180, lung adenocarcinoma and Lewis lung cancer).

It has also inhibited incorporation of two structural units of DNA (uridine and thymidine) in Ehrlich ascites tumor cells, inhibited the growth of P388 leukemia cells, and demonstrated anti-proliferative activity against cell lines of human gastric cancer, lung cancer, lymphoma, and mononuclear leukemia.

Coriolus PSP has reversed tumor-induced immunodeficiencies in sarcoma-bearing mice by increasing immunoglobulin G and C3 complement levels9. It has also been associated with increases in white blood cell count, serum IgG, CD4, CD8, B-lymphocytes, and neutrophils, along with a higher survival rate of tumor bearing mice3. Many of these effects have been attributed to PSP being a strong scavenger of superoxide and hydroxyl radicals. Coriolus Versicolor PSP has also been found to restrict the cell cycle of HL-60 leukemic cells through apoptosis.
These and other immune effects of PSK and PSP are described in reviews by Fisher and Yang, Ooi and Liu and Chu, Ho and Chow.

Source: (mdanderson.org)

See Also:

PSK PSP – Different Extractions of Coriolus Versicolor

Best Places to Buy Coriolus PSP

Coriolus (PSP) & Leukemia Treatment

By on May 19, 2010
This entry is filed under Leukemia, Medical Studies, PSP, Treatments and tagged , , .

From the National Library of Medicine. this short passage relates to how the PSP polysaccharide peptide helps limit damage caused to normal cells during the cancer drug treatment for leukemia:

Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells.

Activation of the cell death program (apoptosis) is a strategy for the treatment of human cancer, and unfortunately a large number of drugs identified as cell cycle-specific agents for killing cancer cells are also toxic to normal cells. The present study demonstrates that the polysaccharide peptide (PSP) extracted from the Chinese medicinal mushroom, Coriolus versicolor, used in combination therapy in China, has the ability to lower the cytotoxicity of certain anti-leukemic drugs via their interaction with cell cycle-dependent and apoptotic pathways. Flow cytometry analysis demonstrated that pre-treatment of PSP (25-100 microg/ml) dose-dependently enhanced the cell cycle perturbation and apoptotic activity of doxorubicin (Doxo) and etoposide (VP-16), but not cytarabine (Ara-C) in human promyelocytic leukemia HL-60 cells. The antagonistic result from combined treatment with Ara-C and PSP may be caused by the removal of HL-60 cells in the G1-S boundary by PSP before exposure to Ara-C. A negative correlation between the increase in apoptotic cell population (pre-G1 peak) with the S-phase cell population expression (R2=0.998), the expression of cyclin E expression (R2=0.872) and caspase 3 activity (R2=0.997) suggests that PSP enhanced the apoptotic machinery of Doxo and VP-16 in a cell cycle-dependent manner and is mediated, at least in part, by the PSP-mediated modulation of the regulatory checkpoint cyclin E and caspase 3. This study is the first to describe the cell cycle mechanistic action of PSP and its interaction with other anticancer agents. Our data support the potential development of PSP as an adjuvant for leukemia treatment, but also imply the importance of understanding its interaction with individual anticancer agents.

Department of Zoology, The University of Hong Kong, Pokfulam Road, Hong Kong, SAR, P.R. China.

See Original post: http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=15944782&dopt=abstractplus

Rss Feed Tweeter button Facebook button Technorati button Linkedin button Webonews button Delicious button Digg button